Sotyktu Gains Ground in Psoriatic Arthritis, but Rheumatologists Remain Selective as Its Role in the Treatment Algorithm Takes Shape, According to Spherix Global Insights

Summary

Spherix Global Insights reports growing prescriber adoption and enthusiasm for Sotyktu's TYK2 differentiation in psoriatic arthritis, though rheumatologists remain selective due to limited experience, access challenges, and questions about joint efficacy.